Stuart Barnscher
Senior Director, Preclinical Programs, ADC Therapeutic Development Zymeworks
Stuart Barnscher is a Senior Director at Zymeworks, leading the discovery and development of next-generation antibody-drug conjugates (ADCs) for hard-to-treat cancers. Advanced multiple programs from concept to clinic, including ZW49, ZW191, and ZW251. Experienced across target validation, antibody discovery & engineering, in vitro biology, and in vivo biology & pharmacokinetics, with a strong track record of bringing IND-ready candidates forward. Former founding Scientist at Kairos Therapeutics, co-developer of the ZymeLink™ Hemiasterlin and Auristatin linker technologies. Lead the discovery of an auristatin drug-linker technology used in the anti-FLT3 ADC, AGS62P1. Passionate about building high-performing teams with a “one team, one mission” culture and driving innovation across every stage of ADC design.
Seminars
- Introducing the in-depth preclinical profile of ZW191 targeting FRα
- Understanding how the design elements of ZW191 manifested in preclinical performance
- Looking ahead: Anticipating clinical impact and outcomes based on reported preclinical activity
